Safety of biweekly α1-antitrypsin treatment in the RAPID programme

Safety of biweekly α₁-antitrypsin treatment in the RAPID programme

Eur Respir J. 2018 Nov 29;52(5):1800897. doi: 10.1183/13993003.00897-2018. Print 2018 Nov.

RAPID Trial Group:
J G W Burdon, R Edwards, A Glanville, M Holmes, P Thompson, M Philipps, P A Wark, R T Abboud, K R Chapman, R K Elwood, P Hernandez, J Chlumsky, N Seersholm, T Skjold, A Altraja, R Mäkitaro, J Ficker, J F Herth, K Schulze, H Teschler, N G McElvaney, J Chorostowska-Wynimko, M Sanak, A Szczeklik, W Z Tomkowsk, P I Stoicescu, T Martynenko, E Piitulainen, M Campos, T J Craig, R A Sandhaus, J M Stocks

¹ Dept of Medicine, Respiratory and Critical Care Medicine, Philipps-University Marburg, Member of the German Center for Lung Diseases (DZL), Marburg, Germany.
² Dept of Pulmonary Diseases, Charles University, Prague, Czech Republic.
³ conresp, Loerzweiler, Germany.
⁴ Clinical Research and Development, CSL Behring, Bern, Switzerland.
⁵ Clinical Strategy and Development, CSL Behring, King of Prussia, PA, USA.
⁶ Statistics Dept, CSL Behring, King of Prussia, PA, USA.
⁷ Global Clinical Safety and Pharmacovigilance, CSL Behring, Marburg, Germany.
⁸ Dept of Medicine, University of Toronto, Toronto, ON, Canada.
⁹ Irish Centre for Genetic Lung disease, Beaumont Hospital, Royal College of Surgeons in Ireland, Dublin, Ireland.
¹⁰ A list of the RAPID Trial Group members can be found in the study group information at the end of this article.

Administration of 120 mg·kg⁻¹ α₁-antitrypsin on a biweekly basis was safe and well tolerated http://ow.ly/CVbz30lUBum

Trial registration: ClinicalTrials.gov NCT00261833 NCT00670007.